ArticleHealthcare (Amsterdam, Netherlands)2021
Commentary: Lessons from the COVID-19 global health response to inform TB case finding.
Article in Healthcare (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Programmatic approaches to screening for tuberculosis disease: a situational analysis of seven countries in the Western Pacific Region.Tropical medicine and health · 2025Article
- Understanding Patient Experiences: A Mixed-Methods Study on Barriers and Facilitators to TB Care-Seeking in South Africa.Tropical medicine and infectious disease · 2025Article
- Incidence of tuberculosis in the city of Cordoba and its relationship with areas in need of social transformation: a study from 2015 to 2021.Central European journal of public health · 2025Observational
- Deprioritized and disrupted: tuberculosis care in the shadow of COVID-19.Frontiers in public health · 2025Article
- Individual journeys to tuberculosis care in Nigeria's private sector during the COVID-19 pandemic.BMJ global health · 2024Article
- The global impact of COVID-19 on tuberculosis: A thematic scoping review, 2020-2023.PLOS global public health · 2024Article
- Ending tuberculosis: challenges and opportunities.Frontiers in tuberculosis · 2024Review
- Lessons for TB from the COVID-19 response: qualitative data from Brazil, India and South Africa.Public health action · 2023Article
- Tuberculosis service disruptions and adaptations during the first year of the COVID-19 pandemic in the private health sector of two urban settings in Nigeria-A mixed methods study.PLOS global public health · 2023Article
- Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel, Switzerland) · 2022Review
- COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia.Journal of multidisciplinary healthcare · 2022Review
- Does tuberculosis screening improve individual outcomes? A systematic review.EClinicalMedicine · 2021Article
- COVID-19 and active primary tuberculosis in a low-resource setting: A case report.Annals of medicine and surgery (2012) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global public health, demanding urgent action and causing unprecedented worldwide change in a short space of time. This disease has devastated economies, infringed on individual freedoms, and taken an unprecedented toll on healthcare systems worldwide. As of 1 April 2020, over a million cases of COVID-19 have been reported in 204 countries and territories, resulting in more than 51,000 deaths. Yet, against the backdrop of the COVID-19 pandemic, lies an older, insidious disease with a much greater mortality. Tuberculosis (TB) is the leading cause of death by a single infectious agent and remains a potent threat to millions of people around the world. We discuss the differences between the two pandemics at present, consider the potential impact of COVID-19 on TB case management, and explore the opportunities that the COVID-19 response presents for advancing TB prevention and control now and in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.